PMID- 35086946 OWN - NLM STAT- MEDLINE DCOM- 20220323 LR - 20220323 IS - 2051-1426 (Electronic) IS - 2051-1426 (Linking) VI - 10 IP - 1 DP - 2022 Jan TI - Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. LID - 10.1136/jitc-2021-003581 [doi] LID - e003581 AB - BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting MAGE-A10(+) tumors in the context of human leukocyte antigen (HLA)-A*02. ADP-0022-003 was a phase I dose-escalation trial that aimed to evaluate the safety and antitumor activity of ADP-A2M10 in non-small cell lung cancer (NSCLC) (NCT02592577). METHODS: Eligible patients were HLA-A*02 positive with advanced NSCLC expressing MAGE-A10. Patients underwent apheresis; T cells were isolated, transduced with a lentiviral vector containing the TCR targeting MAGE-A10, and expanded. Patients underwent lymphodepletion with varying doses/schedules of fludarabine and cyclophosphamide prior to receiving ADP-A2M10. ADP-A2M10 were administered at 0.08-0.12x10(9) (dose group 1), 0.5-1.2x10(9) (dose group 2), and 1.2-15x10(9) (dose group 3/expansion) transduced cells. RESULTS: Eleven patients (male, n=6; female, n=5) with NSCLC (adenocarcinoma, n=8; squamous cell carcinoma, n=3) were treated. Five, three, and three patients received cells in dose group 1, dose group 2, and dose group 3/expansion, respectively. The most frequently reported grade >/=3 adverse events were lymphopenia (n=11), leukopenia (n=10), neutropenia (n=8), anemia (n=6), thrombocytopenia (n=5), and hyponatremia (n=5). Three patients presented with cytokine release syndrome (grades 1, 2, and 4, respectively). One patient received the highest dose of lymphodepletion (fludarabine 30 mg/m(2) on days -5 to -2 and cyclophosphamide 1800 mg/m(2) on days -5 to -4) prior to a second infusion of ADP-A2M10 and had a partial response, subsequently complicated by aplastic anemia and death. Responses included: partial response (after second infusion; one patient), stable disease (four patients), clinical or radiographic progressive disease (five patients), and not evaluable (one patient). ADP-A2M10 were detectable in peripheral blood and in tumor tissue. Peak persistence was higher in patients who received higher doses of ADP-A2M10. CONCLUSIONS: ADP-A2M10 demonstrated an acceptable safety profile and no evidence of toxicity related to off-target binding or alloreactivity. There was persistence of ADP-A2M10 in peripheral blood as well as ADP-A2M10 trafficking into the tumor. Given the discovery that MAGE-A10 and MAGE-A4 expression frequently overlap, this clinical program closed as trials with SPEAR T cells targeting MAGE-A4 are ongoing. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Blumenschein, George R AU - Blumenschein GR AD - Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA gblumens@mdanderson.org. FAU - Devarakonda, Siddhartha AU - Devarakonda S AD - Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Johnson, Melissa AU - Johnson M AD - Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, USA. FAU - Moreno, Victor AU - Moreno V AD - START Madrid-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Gainor, Justin AU - Gainor J AD - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Edelman, Martin J AU - Edelman MJ AD - Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. FAU - Heymach, John V AU - Heymach JV AD - Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Govindan, Ramaswamy AU - Govindan R AD - Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Bachier, Carlos AU - Bachier C AD - Hematology, Sarah Cannon Center for Blood Cancer at TriStar Centennial, Nashville, Tennessee, USA. FAU - Doger de Speville, Bernard AU - Doger de Speville B AD - START Madrid-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Frigault, Matthew J AU - Frigault MJ AD - Bone Marrow Transplant & Cellular Therapy, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. FAU - Olszanski, Anthony J AU - Olszanski AJ AD - Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. FAU - Lam, Vincent K AU - Lam VK AD - Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. FAU - Hyland, Natalie AU - Hyland N AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Navenot, Jean-Marc AU - Navenot JM AD - Adaptimmune, Philadelphia, Pennsylvania, USA. FAU - Fayngerts, Svetlana AU - Fayngerts S AD - Adaptimmune, Philadelphia, Pennsylvania, USA. FAU - Wolchinsky, Zohar AU - Wolchinsky Z AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Broad, Robyn AU - Broad R AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Batrakou, Dzmitry AU - Batrakou D AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Pentony, Melissa M AU - Pentony MM AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Sanderson, Joseph P AU - Sanderson JP AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Gerry, Andrew AU - Gerry A AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Marks, Diane AU - Marks D AD - Adaptimmune, Philadelphia, Pennsylvania, USA. FAU - Bai, Jane AU - Bai J AD - Adaptimmune, Philadelphia, Pennsylvania, USA. FAU - Holdich, Tom AU - Holdich T AD - Adaptimmune, Milton Park, Abingdon, Oxfordshire, UK. FAU - Norry, Elliot AU - Norry E AD - Adaptimmune, Philadelphia, Pennsylvania, USA. FAU - Fracasso, Paula M AU - Fracasso PM AUID- ORCID: 0000-0003-1211-3304 AD - Adaptimmune, Philadelphia, Pennsylvania, USA. LA - eng SI - ClinicalTrials.gov/NCT02592577 PT - Clinical Trial, Phase I PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - England TA - J Immunother Cancer JT - Journal for immunotherapy of cancer JID - 101620585 RN - 0 (Antigens, Neoplasm) RN - 0 (MAGE-A10 antigen) RN - 0 (Neoplasm Proteins) RN - 0 (Receptors, Antigen, T-Cell) SB - IM MH - Aged MH - Antigens, Neoplasm/*immunology MH - Carcinoma, Non-Small-Cell Lung/*therapy MH - Female MH - Genetic Engineering MH - Humans MH - *Immunotherapy, Adoptive/adverse effects MH - Lung Neoplasms/*therapy MH - Lymphocyte Depletion MH - Male MH - Middle Aged MH - Neoplasm Proteins/*immunology MH - Receptors, Antigen, T-Cell/*immunology MH - T-Lymphocytes/*immunology PMC - PMC8796260 OTO - NOTNLM OT - cell engineering OT - clinical trials as topic COIS- Competing interests: AG holds stock options in Adaptimmune. AJO has received research contracts from Alkermes, Antegene, Astellas, Checkmate, Gan & Lee, GlycoNex, InstilBio, Intensity, Istari, Kadmon, Kartos, NeoImmune, NGM, OncoSec, Sound Bio, SpringBank, Takeda; has received payment for advisory board roles from Merck, BMS, Pfizer, Takeda, Sanofi, Eisai. DB, DM, EN, JB, J-MN, JPS, MMP, NH, RB, SF are or were employees of Adaptimmune at the time of the study. GRB has received grants/contracts from Amgen, Bayer, Adaptimmune, Elelixis, Daiichi Sankyo, GlaxoSmithKline, Immatics, Immunocore, Incyte, Kite Pharma, Macrogenics, Torque, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, MedImmune, Merck, Novartis, Roche, Xcovery, Tmunity Therapeutics, Regeneron, Beigene, Repertoire Immune Medicines, Verastem; consulting fees from Abbvie, Adicet, Amgen, Ariad, Bayer, Clovis Oncology, AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Instil Bio, Genentech, Gilead, Lilly, Janssen, MedImmune, Merck, Novartis, Roche, Tyme Oncology, Xcovery, Virogin Biotech, Maverick Therapeutics; has participated on a Data Safety Monitoring Board or Advisory Board for Virogen Biotech, Maverick Therapeutics; holds stock or stock options in Virogin Biotech; and has other financial or non-financial interests in Johnson & Johnson/Janssen (immediate family member employed). JG has been a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Jounce, Karyopharm, GlydeBio, Mirati, AstraZeneca, Regeneron, Oncorus, Helsinn, Array, and Clovis Oncology; has been an employee (immediate family member) with equity in Ironwood Pharmaceuticals; has received research funding from Novartis, Genentech/Roche, and Ariad/Takeda; has received institutional research support from Tesaro, Moderna, Blueprint, Scholar Rock, BMS, Array, Adaptimmune, Novartis, Genentech/Roche, Alexo and Merck. JVH has received grants/contracts from AstraZeneca, GlaxoSmithKline and Spectrum; holds royalty/licenses in Spectrum; has received consulting fees from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, RefleXion; has received honoraria from Medlinker, Peerview, Nexus Health Medicine, Targeted Oncology, MJH Events; has received support for attending meetings from IASLC Targeted Therapies, IASLC World Conference on Lung Cancer; has been in a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Mechanisms of Cancer Therapeutics-1 (MCT1) (Study Section - Chair). MJ has received research funding from AbbVie, Acerta, Adaptimmune, Apexigen, Array BioPharma, AstraZeneca, Atreca, BeiGene, Boehringer Ingelheim, Checkpoint Therapeutics, Corvus Pharmaceuticals, CytomX, Daiichi Sankyo, Dynavax, Lilly, EMD Serono, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Merck, Mirati Therapeutics, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Sanofi, Seven and Eight Biopharmaceuticals, Shattuck Labs, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, University of Michigan, WindMIL, TCR2 Therapeutics, Arcus Biosciences, Ribon Therapeutics, Amgen; has held a consulting/advisory role (spouse) for Astellas, Otsuka Pharmaceuticals; has held a consulting/advisory role (self) for AbbVie, Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Calithera Biosciences, Genentech, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, Association of Community Cancer Center; has received food/beverage/travel expenses from Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Clovis, Daiichi Sankyo, EMD Serono, Bristol Myers Squibb, Exelixis, Genentech/Roche, Incyte, Merck, Pfizer, Sysmex Inostics, Vapotherm, Janssen, Lilly, Novartis, Sanofi. MJE has received research funding from GlaxoSmithKline, Mersana, Amgen, Windmil, Nektar, Apexigen, Adaptimmune; has received consulting fees from Kanaph, Flame; has received honoraria from Sanofi; has been a member of DSMB for AstraZeneca, Seattle Genetics, GlaxoSmithKline, Takeda; has been a consultant/on an advisory board for Windmil, Regeneron, Syndax; has been the Chair, Scientific Advisory board for Lung Cancer Foundation of America; has been the Deputy Editor of 'Lung Cancer'; has received stock options from Biomarker strategies; Creatv Biotech. MJF has been a consultant for Arcellx, BMS, Novartis, Kite, Iovance. PMF is an employee of Adaptimmune; holds stock in Adaptimmune and Bristol-Myers Squib; has received compensation for travel and congress meetings. RG has received consulting fees from BMS, Abbvie, Geneplus; has participated on a Data Safety Monitoring Board or Advisory Board for Roche Genentech. SD has been a consultant for Jacobio pharmaceuticals (without financial compensation). TH was an employee of Adaptimmune at the time of the study; has been a consultant for Adaptimmune. VKL has been in a consulting or advisory role for Takeda, Bristol-Myers Squibb, Seattle Genetics; has received research funding from GlaxoSmithKline, Bristol-Myers Squibb, Guardant Health, Takeda. VM has received consulting fees from Roche, Bayer, Pieris, BMS, Janssen and Basilea. BDdS, CB, ZW have nothing to declare. EDAT- 2022/01/29 06:00 MHDA- 2022/03/24 06:00 PMCR- 2022/01/27 CRDT- 2022/01/28 05:51 PHST- 2021/10/27 00:00 [accepted] PHST- 2022/01/28 05:51 [entrez] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/03/24 06:00 [medline] PHST- 2022/01/27 00:00 [pmc-release] AID - jitc-2021-003581 [pii] AID - 10.1136/jitc-2021-003581 [doi] PST - ppublish SO - J Immunother Cancer. 2022 Jan;10(1):e003581. doi: 10.1136/jitc-2021-003581.